Page last updated: 2024-11-11

cyclosporine metabolite m17

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cyclosporin A metabolite M17 : A cyclosporin A derivative that is cyclosporin A in which residue 1 [(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid] has undergone allylic oxidation to give the corresponding primary allylic alcohol. It specifically inhibits growth of renal cells in culture. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10653928
CHEMBL ID2407580
CHEBI ID140154
MeSH IDM0146607

Synonyms (15)

Synonym
CHEBI:140154
cyclosporin metabolite am1
89270-28-0
ol-17
(3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(1r,2r,4e)-1,6-dihydroxy-2-methylhex-4-en-1-yl]-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23
csa m17
ol 17
cyclosporine a metabolite m17
6-[(2s,3r,4r,6e)-3,8-dihydroxy-4-methyl-2-(methylamino)-6-octenoic acid]cyclosporin
cyclosporin a metabolite m17
cyclosporine metabolite m17
CHEMBL2407580
cyclosporin am 1 (>80%)
(3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-((1r,2r,e)-1,6-dihydroxy-2-methylhex-4-en-1-yl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,2
STARBLD0037844

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" On both study days Cmax, and tmax of cyclosporin were not significantly different."( Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD.
Blick, S; Franzke, A; Jacobsen, W; Kirchner, GI; Manns, MP; Mueller, L; Sewing, KF; Vidal, C; Wagner, S; Winkler, M, 2000
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Thus CyA dosage must be calculated to avoid the risks of organ rejection through underdosage and toxic organ damage through overdosage or accumulation of metabolites."( Rapid, sensitive high-performance liquid chromatographic method for the determination of cyclosporin A and its metabolites M1, M17 and M21.
Auer, T; Iberer, F; Khoschsorur, G; Petek, W; Rödl, S; Semmelrock, HJ; Tscheliessnigg, KH, 1997
)
0.3
" Because CyA and its metabolites have nephrotoxic, hepatotoxic, and neurotoxic side effects, CyA dosage must be calculated to avoid the risk of organ rejection through underdosage and toxic organ damage through overdosage or accumulation of metabolites."( The determination of metabolite M17 and its meaning for immunosuppressive cyclosporin therapy.
Auer, T; Holzer, H; Khoschsorur, G; Lanzer, G; Petritsch, P; Tscheliessnigg, KH, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
drug metabolitenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cyclosporin A derivativeAny homodetic cyclic peptide whose structure is derived from cyclosporin A. The term includes metabolites of cyclosporin A.
primary allylic alcoholAn allylic alcohol in which the carbon atom that links the double bond to the hydroxy group is also attached to two hydrogens.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID762654Antiviral activity against HIV1 3B infected in human MT4 cells coinfected with HTLV1 assessed as reduction in virus-induced cytopathogenicity after 4 days by MTT assay2013Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16
Cyclophilin inhibitors as antiviral agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (62.07)18.7374
1990's9 (31.03)18.2507
2000's1 (3.45)29.6817
2010's1 (3.45)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]